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Abstract. Vanadium is a soft, silvery-grey metal with a 
number of different oxidation states. The most common 
commercial form of vanadium is vanadium pentoxide (V2O5). 
All vanadium compounds are considered toxic. An increase in 
skin rashes has been observed in certain vanadium workers, 
including the development of atopic dermatitis. However, to 
the best of our knowledge, no prior in vivo or in vitro studies 
have evaluated the effect of vanadium exposure in human 
dermal fibroblasts. The present study evaluated the effect 
of V2O5 on proliferation and chemokine secretion in dermal 
fibroblasts. The results revealed that V2O5 had no significant 
effect on the viability or proliferation of fibroblasts, however it 
was able to induce the secretion of T-helper (Th)1 chemokines 
from dermal fibroblasts, synergistically increasing the effect 
of important Th1 cytokines, including interferon-γ and tumor 
necrosis factor-α. Through these processes, V2O5 may lead to 
the induction and perpetuation of an inflammatory reaction in 
dermal tissue. The induction and perpetuation of inflammation 
in the dermis and the variety of involved candidate genes may 
be at the base of V2O5-induced effects following occupational 
and environmental exposures. Further studies are necessary to 
evaluate dermal integrity and manifestations in subjects who 
are occupationally exposed, or living in polluted areas.
Introduction
Vanadium is a soft, silvery-grey metal, which exists in a 
number of different oxidation states (-1, 0, +2, +3, +4 and +5); 
vanadium pentoxide (V2O5) is the most common commercial 
form, and most of the studies on toxicity have been conducted 
on vanadium pentoxide, as it is the primary form found in 
industrial exposure situations (1). All vanadium compounds 
are considered toxic. The Occupational Safety and Health 
Administration (Bellevue, WA, USA) have set an exposure 
limit for the workplace (considering an 8 h workday, and a 
40 h work week), of 0.05 mg/m3 for V2O5 dust and 0.1 mg/m3 
for V2O5 fumes (2).
The exposure dose of vanadium that is considered life- 
threatening is 35 mg/m3 [as determined by the National Institute 
for Occupational Safety and Health (NIOSH; Washington, 
DC, USA)], which could cause serious and perpetuating health 
issues, including death (2). The respiratory system is the 
most vulnerable to vanadium toxicity, while the effect on the 
gastrointestinal system is minimal due to the low gut absorp-
tion rate (3-5). However, quantitative data are not sufficient to 
obtain a chronic or subchronic inhalation reference dose.
In rat models, the effects resulting from an inhaled or oral 
vanadium were evaluated in the sera (6,7), nervous tissue (8), 
liver (9) and other types of tissue (kidney, gut, lungs) develop-
ment (10). In vanadium workers (NIOSH 1983) increases in 
skin rashes and atopic dermatitis have been recorded. To the 
best of our knowledge, no prior in vivo or in vitro studies have 
been conducted to evaluate the effect of vanadium exposure 
on dermal fibroblasts. Here, we evaluated the effect of V2O5 on 
the proliferation and chemokine secretion profiles of dermal 
fibroblasts.
Materials and methods
Fibroblast cell cultures. Dermal fibroblasts were obtained 
from 6 patients who underwent surgery for thyroid nodular 
goiter (discarded dermal material was used). The local Ethics 
Committee of the University of Pisa approved the study 
protocol, and all subjects provided informed consent.
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As previously described, tissue explants from the derma 
were minced and placed in culture dishes, to allow the 
fibroblasts to proliferate (11). Fibroblasts were propagated in 
Medium 199 containing 20% FBS (Gibco; Invitrogen, Ltd., 
Paisley, UK), gentamycin (20 µg/ml) and penicillin (100 U/ml), 
in a 37˚C humidified incubator with 5% of CO2. Cells were 
subsequently maintained in medium 199 containing 10% FBS 
(and antibiotics) (12).
Cell viability and proliferation assay. The evaluation of cell 
proliferation and viability was conducted using a WST-1 assay 
(Roche Diagnostics, Almere, The Netherlands), which uses 
MTT (13,14). Fibroblasts were seeded (35,000 cells/ml, in a 
final volume of 100 µl) into 96‑well plates. The effect V2O5 
on fibroblast proliferation was determined following exposure 
of the cells for 24 h to increasing concentrations of V2O5 
(1, 10 and 100 nM). Cells were then plated and treated for 
24 h with V2O5, or with its vehicle alone; all experiments were 
performed in triplicate for each cell preparation.
Proliferation assay: cell counting. The cell counting assay was 
also used to assess fibroblast proliferation (13,14).
Chemokines secretion assays. Chemokine (C-X-C motif) 
ligand (CXCL)9 and CXCL10 secretion assays were performed 
by seeding 30,000 cells/ml into 96‑well plates, with a final 
volume of 100 µl/well, in growth medium that was removed 
after 24 h. Cells were subsequently washed in PBS, then 
incubated (24 h) in phenol red and serum-free medium with 
interferon (IFN)-γ (R&D Systems, Minneapolis, MN, USA; 
500; 1,000; 5,000; 10,000 IU/ml), and/or 10 ng/ml tumor 
necrosis factor (TNF)-α (R&D Systems) (11). Preliminary 
experiments were conducted to select the TNF-α concen-
tration, in order to obtain the highest secretion rate. The 
supernatants were collected after 24 h, then frozen at ‑20˚C 
until use in the chemokine assay.
To understand the effect of V2O5 on the chemokine secretion 
induced by IFN-γ, cells were treated for 24 h with increasing 
concentrations of V2O5 (1, 10 and 100 nM), in the presence or 
absence of IFN-γ (1,000 IU/ml), and/or TNF-α (10 ng/ml). An 
ELISA was used to measure the CXCL9 and CXCL10 levels in 
the supernatants. The experiments were performed three times 
for each different cell preparation.
ELISA for CXCL9 and CXCL10. CXCL9 and CXCL10 were 
assessed in the supernatants obtained from cell cultures, using 
commercially available kits (R&D Systems). The minimum 
(mean) detectable doses were 1.5 and 1.2 pg/ml for CXCL9 and 
CXCL10, respectively. The intra‑ and inter‑assay coefficients of 
variation were 3.5 and 6.4% respectively, for CXCL9, and 4.5 and 
7.3% respectively, for CXCL10. Quality control pools of normal, 
low and high concentrations were also included in each assay.
Data analysis. For normally distributed variables, values are 
given as the mean ± SD in text, and in figures, otherwise as 
the median and interquartile range. Mean group values were 
compared using one-way analysis of variance (ANOVA) 
for variables normally distributed variables, or by using the 
Kruskal-Wallis test or Mann-Whitney U test. Proportions 
were compared using the Chi-square test. In addition, the 
Bonferroni-Dunn test was used for the post hoc comparison of 
normally distributed variables.
Results
Cell proliferation. The WST-1 cell viability and prolifera-
tion assay showed that V2O5 (1, 10 and 100 nM) did not alter 
the viability or proliferation of dermal fibroblasts (Fig. 1). 
These results were confirmed by a cell counting assay 
(data not presented).
CXCL9. CXCL9 was not detectable in the supernatants 
gathered from primary fibroblast samples, whereas its 
concentration was elevated following IFN-γ dose-dependent 
induction (0, 75±31, 141±29, 210±35 and 297±74 pg/ml for 
IFN-γ 0; 500; 1,000; 5,000 and 10,000 IU/ml, respectively; 
P<0.001, ANOVA). TNF-α alone had no significant impact on 
CXCL9, which remained undetectable, whereas IFN-γ plus 
TNF-α exhibited a synergistic effect on the CXCL9 release 
(CXCL9, 11,154±1,673 vs. 151±42 pg/ml with IFN-γ alone; 
P<0.0001, ANOVA).
CXCL9 release was dose-dependently stimulated 
(P<0.0001, ANOVA) when fibroblasts were treated with 
increasing V2O5 concentrations (1, 10 and 100 nM) (Fig. 2A). 
Following the treatment of fibroblasts with V2O5 (1, 10 and 
100 nM), together with TNF-α, CXCL9 secretion was not 
significantly changed with respect to V2O5 alone (data not 
presented). Treating fibroblasts with 100 nM V2O5 plus IFN-γ 
induced a synergistic increase in CXCL9 release (P<0.0001, 
ANOVA) (Fig. 3A). When fibroblasts were treated with V2O5 
(100 nM), together with IFN-γ and TNF-α stimulation, CXCL9 
release was synergistically increased (P<0.0001, ANOVA) 
(Fig. 4A).
CXCL10. CXCL10 was also not detectable in the supernatants 
obtained from primary fibroblast cultures under basal condi-
tions. IFN-γ induced CXCL10 secretion dose-dependently 
(0, 34±18, 107±42, 187±32 and 272±76 pg/ml, respectively, for 
IFN-γ 0; 500; 1,000; 5,000; 10,000 IU/ml; ANOVA, P<0.001). 
TNF-α alone did not have a significant impact on CXCL10 
secretion, whereas IFN-γ plus TNF-α exhibited a synergistic 
Figure 1. The WST-1 cell viability and proliferation assay showed that V2O5 
(1, 10 and 100 nM) does not alter the viability or proliferation of dermal 
fibroblasts (mean group values were compared using one‑way analysis of 
variance; the Bonferroni-Dunn test was used for post hoc comparisons; 
P>0.05 for all comparisons). V2O5, vanadium pentoxide.
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effect on CXCL10 secretion (3,043±234 vs. 117±27 pg/ml with 
IFN-γ alone; P<0.0001, ANOVA).
CXCL10 release was dose-dependently stimulated 
(P<0.0001, ANOVA) when fibroblasts were treated with 
increasing V2O5 concentrations (1, 10 and 100 nM) (Fig. 2B). 
Following the treatment of fibroblasts with V2O5 (1, 10 and 
100 nM), and together with TNF-α, CXCL10 secretion 
was not significantly changed with respect to V2O5 alone 
(data not presented).
Treating fibroblasts with 100 nM V2O5 plus IFN-γ 
caused a synergistic increase in CXCL10 release (P<0.0001, 
ANOVA) (Fig. 3B). When fibroblasts were treated with 
V2O5 (100 nM) together with IFN-γ and TNF-α stimulation, 
CXCL10 release was also synergistically increased (P<0.0001, 
ANOVA) (Fig. 4B).
Discussion
The results of the present study demonstrated that V2O5 
could promote IFN-γ-dependent chemokine secretion in 
dermal fibroblasts, without altering their cell proliferation and 
viability. In addition, our results confirmed that IFN‑γ and 
TNF-α stimulate CXCL9 and CXCL10 secretion, as hypothe-
sized (11,15). It is notable that V2O5 was able to synergize with 
IFN-γ and TNF-α, further increasing chemokines secretion.
These results are concordant with the hypothesis that V2O5 
is able to induce and perpetuate inflammation in the dermal 
tissues, evolving from a predominant T-helper (Th)1 immune 
response (13). IFN-γ-inducible C-X-C chemokines are secreted 
by several types of mammalian cells, including fibroblasts, 
Figure 4. Treating dermal fibroblasts with V2O5 (100 nM), together with 
IFN-γ plus TNF-α, synergistically increased (A) CXCL9 and (B) CXCL10 
secretion (P<0.0001 by one-way analysis of variance). Bonferroni-Dunn 
test was used for post hoc comparisons. *P<0.05 vs. the control; **P<0.05 
vs. IFN+TNF. V2O5, vanadium pentoxide; CXCL, chemokine (C-X-C motif) 
ligand; IFN, interferon; TNF, tumor necrosis factor.
Figure 3. Treating dermal fibroblasts with V2O5 (100 nM), together with IFN-γ, 
synergistically increased (A) CXCL9 and (B) CXCL10 release (P<0.0001 by 
one-way analysis of variance). Bonferroni-Dunn test was used for post hoc 
comparisons. *P<0.05 vs. the control; #P<0.05 vs. IFN; oP<0.05 vs. V2O5. V2O5, 
vanadium pentoxide; CXCL, chemokine (C-X-C motif) ligand; IFN, interferon.
Figure 2. Following the treatment of dermal fibroblasts with V2O5 (1, 10 
and 100 nM), (A) CXCL9 and (B) CXCL10 secretion was dose-dependently 
stimulated (P<0.0001 by one-way analysis of variance). Bonferroni-Dunn 
test was used for post hoc comparisons. *P<0.05 vs. the control. V2O5, vana-
dium pentoxide; CXCL, chemokine (C-X-C motif) ligand.
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thyrocytes, islet cells, colon epithelial cells and endothelial 
cells, among others (11,13-21). These cell types are unable to 
produce these chemokines under basal conditions; they are 
induced following stimulation by IFN-γ (alone or in combina-
tion with TNF-α), a cytokine that is produced by Th1-activated 
lymphocytes in several autoimmune diseases, including in the 
thyroid in Graves' disease, and in autoimmune thyroiditis. It 
has been hypothesized that this process can be involved in the 
initiation and/or the perpetuation of various autoimmune disor-
ders (11,13-21), and that it may also be applied to the thyroid.
Our results are concordant with those of other studies in 
different cell types. V2O5 exposure is a cause of occupational 
bronchitis; an in vitro study was conducted to evaluate the gene 
expression profiles of human lung fibroblasts following V2O5 
exposure, in order to identify genes that might play a role in the 
bronchial inflammation, repair and fibrosis during the patho-
genesis of bronchitis. A dozen genes are overexpressed by V2O5, 
including CXCL9 and CXCL10 (1). A further study reported that 
fibroblasts responded to vanadium oxidative stress by producing 
IFN-β and activating STAT-1, which lead to increased CXCL10 
levels (22), thus serving a role in the innate immune response.
It is notable that vanadium is able to increase chemokine 
secretion in the dose range of 1-100 nM. Since the normal 
blood levels of vanadium range from 0.45-18.4 nM, 100 nM 
could be noted as a dose that might mimic an abnormally high 
exposure (23). Thus, we could hypothesize that V2O5 in this 
concentration range is able to induce an inflammatory reaction 
in dermal tissues, prompting the appearance of skin rashes or 
atopic dermatitis.
Moreover, it has been shown that exposure of human skin 
fibroblasts to vanadate causes DNA strand breaks at relevant 
concentration of 1 µM (24). In the present study we have 
considered lower concentrations (1, 10 and 100 nM), that did 
not alter the viability or proliferation of dermal fibroblasts.
In conclusion, the results of our study showed that V2O5 is 
able to induce Th1 chemokine secretion in dermal tissues, and 
that it can synergize with important Th1 cytokines (such as 
IFN-γ and TNF-α), leading to the induction and perpetuation 
of inflammation in the dermis. Moreover, different genes are 
overexpressed by V2O5, including CXCL9 and CXCL10, that 
appear to have important functions in inflammation, fibrosis 
and repair. To the best of our knowledge, no prior study has 
evaluated the immune modulatory effects of vanadium in 
dermal fibroblasts; therefore, our results could be important 
for evaluating the pathogenesis of clinical dermatological 
manifestations of vanadium exposure in humans. The induc-
tion and perpetuation of inflammation in the dermis and the 
variety of involved candidate genes could be at the basis of 
V2O5-induced effects after occupational and environmental 
exposures. Additional studies are required to assess dermal 
integrity, as well as the manifestations of toxicity in subjects 
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